| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Altitude Sickness | 16 | 2016 | 92 | 4.730 |
Why?
|
| Altitude | 10 | 2014 | 161 | 2.230 |
Why?
|
| Mountaineering | 8 | 2015 | 45 | 2.070 |
Why?
|
| Hemoglobins, Abnormal | 4 | 2021 | 119 | 1.640 |
Why?
|
| Pulmonary Edema | 5 | 2011 | 414 | 1.270 |
Why?
|
| Blood Coagulation Factors | 2 | 2019 | 355 | 1.110 |
Why?
|
| Cyanosis | 2 | 2015 | 83 | 0.980 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 8 | 2013 | 1378 | 0.860 |
Why?
|
| Triticum | 3 | 2019 | 86 | 0.860 |
Why?
|
| von Willebrand Diseases | 2 | 2021 | 127 | 0.800 |
Why?
|
| Acetazolamide | 4 | 2013 | 100 | 0.720 |
Why?
|
| Blood Coagulation Tests | 5 | 2022 | 263 | 0.710 |
Why?
|
| Seeds | 2 | 2013 | 105 | 0.690 |
Why?
|
| Paraneoplastic Syndromes, Nervous System | 1 | 2019 | 23 | 0.680 |
Why?
|
| Cadmium | 3 | 2019 | 212 | 0.680 |
Why?
|
| Carbonic Anhydrase Inhibitors | 3 | 2013 | 95 | 0.640 |
Why?
|
| Hodgkin Disease | 10 | 2013 | 1415 | 0.630 |
Why?
|
| von Willebrand Factor | 2 | 2021 | 669 | 0.630 |
Why?
|
| Intracranial Hypertension | 3 | 2016 | 186 | 0.610 |
Why?
|
| Lymphoma, B-Cell | 8 | 2010 | 931 | 0.600 |
Why?
|
| Utilization Review | 1 | 2019 | 392 | 0.600 |
Why?
|
| Nepal | 7 | 2015 | 295 | 0.560 |
Why?
|
| Intracranial Pressure | 3 | 2016 | 326 | 0.550 |
Why?
|
| Hemolysis | 2 | 2019 | 420 | 0.510 |
Why?
|
| Benzocaine | 1 | 2014 | 15 | 0.490 |
Why?
|
| Osteomalacia | 1 | 2014 | 53 | 0.490 |
Why?
|
| Optic Nerve | 2 | 2008 | 554 | 0.480 |
Why?
|
| Rescue Work | 1 | 2014 | 56 | 0.480 |
Why?
|
| Temazepam | 1 | 2013 | 6 | 0.480 |
Why?
|
| Methemoglobinemia | 1 | 2014 | 44 | 0.480 |
Why?
|
| Hemangiopericytoma | 1 | 2014 | 77 | 0.480 |
Why?
|
| Nitrous Oxide | 1 | 2015 | 177 | 0.470 |
Why?
|
| Sleep Disorders, Intrinsic | 1 | 2013 | 15 | 0.470 |
Why?
|
| Vitamin B 12 Deficiency | 1 | 2015 | 116 | 0.470 |
Why?
|
| Myelin Sheath | 2 | 2008 | 652 | 0.470 |
Why?
|
| Color | 1 | 2015 | 307 | 0.470 |
Why?
|
| Hypophosphatemia | 1 | 2014 | 85 | 0.460 |
Why?
|
| Blood Coagulation | 2 | 2022 | 1127 | 0.440 |
Why?
|
| Skiing | 1 | 2012 | 24 | 0.430 |
Why?
|
| Blood | 1 | 2015 | 598 | 0.420 |
Why?
|
| Herpesvirus 4, Human | 9 | 2012 | 1041 | 0.420 |
Why?
|
| Ultrasonography | 5 | 2012 | 5985 | 0.420 |
Why?
|
| Dextroamphetamine | 1 | 2012 | 129 | 0.420 |
Why?
|
| Thoracic Neoplasms | 1 | 2014 | 268 | 0.410 |
Why?
|
| Iron Overload | 1 | 2014 | 242 | 0.410 |
Why?
|
| Spinal Cord Diseases | 1 | 2015 | 298 | 0.400 |
Why?
|
| Immunophenotyping | 12 | 2013 | 1880 | 0.400 |
Why?
|
| Autoantibodies | 2 | 2019 | 2035 | 0.400 |
Why?
|
| Amphetamine | 1 | 2012 | 225 | 0.390 |
Why?
|
| Anemia, Hemolytic | 1 | 2012 | 168 | 0.390 |
Why?
|
| Anemia | 2 | 2018 | 1506 | 0.390 |
Why?
|
| Vegetables | 1 | 2016 | 1182 | 0.360 |
Why?
|
| Food Supply | 1 | 2016 | 524 | 0.360 |
Why?
|
| Acclimatization | 1 | 2010 | 103 | 0.350 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 2014 | 365 | 0.350 |
Why?
|
| Pancreatitis | 3 | 2012 | 1092 | 0.350 |
Why?
|
| Foxes | 1 | 2009 | 9 | 0.340 |
Why?
|
| Factor Xa | 1 | 2010 | 162 | 0.340 |
Why?
|
| Rabies Vaccines | 1 | 2009 | 31 | 0.340 |
Why?
|
| Lymphoma | 5 | 2012 | 1877 | 0.330 |
Why?
|
| Rabies | 1 | 2009 | 61 | 0.330 |
Why?
|
| Refugees | 1 | 2016 | 511 | 0.320 |
Why?
|
| Disease Reservoirs | 1 | 2009 | 131 | 0.320 |
Why?
|
| Drug Monitoring | 3 | 2013 | 956 | 0.320 |
Why?
|
| Bites and Stings | 1 | 2009 | 91 | 0.320 |
Why?
|
| Intraocular Pressure | 1 | 2013 | 1270 | 0.310 |
Why?
|
| Emergency Treatment | 3 | 2007 | 517 | 0.310 |
Why?
|
| Eye Neoplasms | 2 | 2007 | 313 | 0.300 |
Why?
|
| Epstein-Barr Virus Infections | 3 | 2009 | 570 | 0.300 |
Why?
|
| Herpesviridae Infections | 1 | 2009 | 277 | 0.300 |
Why?
|
| Thromboembolism | 2 | 2020 | 986 | 0.300 |
Why?
|
| Blood Cell Count | 2 | 2005 | 403 | 0.290 |
Why?
|
| Heparin | 3 | 2011 | 1637 | 0.290 |
Why?
|
| Anesthetics, Local | 1 | 2014 | 985 | 0.290 |
Why?
|
| Humans | 105 | 2022 | 744343 | 0.290 |
Why?
|
| Lacrimal Apparatus Diseases | 1 | 2007 | 65 | 0.280 |
Why?
|
| Residence Characteristics | 2 | 2016 | 2050 | 0.280 |
Why?
|
| Amlodipine | 1 | 2006 | 83 | 0.280 |
Why?
|
| Oxygen Consumption | 2 | 2010 | 1869 | 0.280 |
Why?
|
| Conjunctival Neoplasms | 1 | 2007 | 79 | 0.270 |
Why?
|
| Lymphoma, Follicular | 5 | 2012 | 435 | 0.260 |
Why?
|
| Splenic Neoplasms | 1 | 2006 | 100 | 0.260 |
Why?
|
| Hypnotics and Sedatives | 1 | 2013 | 1162 | 0.260 |
Why?
|
| Iron | 1 | 2014 | 1774 | 0.260 |
Why?
|
| Lymphoma, AIDS-Related | 1 | 2005 | 84 | 0.260 |
Why?
|
| Orbital Neoplasms | 2 | 2007 | 225 | 0.260 |
Why?
|
| T-Lymphocytes | 6 | 2016 | 10180 | 0.250 |
Why?
|
| Hematology | 2 | 2005 | 221 | 0.250 |
Why?
|
| Emergency Medicine | 1 | 2014 | 1207 | 0.250 |
Why?
|
| Neoplasms, Multiple Primary | 2 | 2006 | 604 | 0.250 |
Why?
|
| Hypertension, Pulmonary | 2 | 2012 | 1537 | 0.250 |
Why?
|
| Herpesvirus 8, Human | 4 | 2009 | 258 | 0.250 |
Why?
|
| Emergency Medical Services | 2 | 2014 | 1917 | 0.250 |
Why?
|
| Plant Roots | 3 | 2013 | 109 | 0.250 |
Why?
|
| Lymphoma, Non-Hodgkin | 3 | 2007 | 1381 | 0.240 |
Why?
|
| Hematopoiesis | 1 | 2014 | 2072 | 0.240 |
Why?
|
| Adult | 54 | 2020 | 214055 | 0.230 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2007 | 367 | 0.230 |
Why?
|
| Heart Septal Defects, Atrial | 1 | 2007 | 478 | 0.230 |
Why?
|
| HIV Seropositivity | 2 | 2007 | 971 | 0.230 |
Why?
|
| Mass Screening | 1 | 2019 | 5255 | 0.220 |
Why?
|
| Body Fluids | 1 | 2005 | 319 | 0.220 |
Why?
|
| Calcium Channel Blockers | 1 | 2006 | 690 | 0.220 |
Why?
|
| Anticoagulants | 4 | 2022 | 4599 | 0.220 |
Why?
|
| Adaptation, Physiological | 1 | 2010 | 1312 | 0.220 |
Why?
|
| Male | 61 | 2020 | 350118 | 0.220 |
Why?
|
| Blood Chemical Analysis | 1 | 2005 | 440 | 0.220 |
Why?
|
| Vasodilator Agents | 1 | 2007 | 977 | 0.210 |
Why?
|
| Lymph Nodes | 11 | 2012 | 3474 | 0.210 |
Why?
|
| Athletic Injuries | 1 | 2012 | 1154 | 0.210 |
Why?
|
| Ferritins | 2 | 2016 | 590 | 0.210 |
Why?
|
| Ibuprofen | 1 | 2003 | 236 | 0.200 |
Why?
|
| Pulmonary Artery | 1 | 2010 | 1912 | 0.190 |
Why?
|
| Platelet Aggregation | 2 | 2018 | 798 | 0.190 |
Why?
|
| Gene Rearrangement | 4 | 2012 | 1179 | 0.190 |
Why?
|
| Female | 58 | 2020 | 380194 | 0.190 |
Why?
|
| Hemoglobins | 2 | 2019 | 1534 | 0.190 |
Why?
|
| Leukemia | 2 | 2016 | 1511 | 0.180 |
Why?
|
| Hypotension | 1 | 2006 | 884 | 0.180 |
Why?
|
| Middle Aged | 42 | 2020 | 213383 | 0.180 |
Why?
|
| Corpus Callosum | 1 | 2005 | 737 | 0.180 |
Why?
|
| Plant Shoots | 2 | 2013 | 25 | 0.180 |
Why?
|
| Wounds and Injuries | 1 | 2012 | 2400 | 0.170 |
Why?
|
| Immunohistochemistry | 14 | 2011 | 11366 | 0.170 |
Why?
|
| Receptors, Purinergic P2Y12 | 1 | 2020 | 132 | 0.170 |
Why?
|
| Acetaminophen | 1 | 2003 | 545 | 0.170 |
Why?
|
| Hemostasis | 1 | 2021 | 458 | 0.170 |
Why?
|
| Lymphoproliferative Disorders | 3 | 2009 | 523 | 0.170 |
Why?
|
| Trypsin | 1 | 2019 | 511 | 0.170 |
Why?
|
| Acute Disease | 6 | 2016 | 7149 | 0.170 |
Why?
|
| Headache | 2 | 2005 | 1226 | 0.160 |
Why?
|
| Comet Assay | 1 | 2018 | 71 | 0.160 |
Why?
|
| Hemophilia A | 1 | 2021 | 351 | 0.160 |
Why?
|
| Substance-Related Disorders | 1 | 2015 | 4258 | 0.160 |
Why?
|
| Partial Thromboplastin Time | 3 | 2022 | 206 | 0.160 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 2 | 2011 | 134 | 0.160 |
Why?
|
| Killer Cells, Natural | 1 | 2007 | 2133 | 0.160 |
Why?
|
| Diagnosis, Differential | 13 | 2013 | 12959 | 0.160 |
Why?
|
| Neurosurgical Procedures | 2 | 2020 | 2002 | 0.160 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2021 | 11725 | 0.160 |
Why?
|
| Platelet Aggregation Inhibitors | 3 | 2020 | 3068 | 0.150 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 3 | 2010 | 180 | 0.150 |
Why?
|
| In Situ Hybridization | 7 | 2012 | 1950 | 0.150 |
Why?
|
| Fibrin | 1 | 2019 | 506 | 0.150 |
Why?
|
| Biological Assay | 1 | 2020 | 652 | 0.140 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 1 | 2020 | 361 | 0.140 |
Why?
|
| Platelet Function Tests | 2 | 2020 | 270 | 0.140 |
Why?
|
| Flow Cytometry | 8 | 2011 | 5974 | 0.140 |
Why?
|
| Lymphoma, T-Cell | 3 | 2009 | 299 | 0.140 |
Why?
|
| Queensland | 1 | 2016 | 37 | 0.140 |
Why?
|
| Immunoglobulin Heavy Chains | 3 | 2010 | 659 | 0.140 |
Why?
|
| Fibrinogen | 1 | 2019 | 894 | 0.140 |
Why?
|
| Biomedical Research | 1 | 2011 | 3309 | 0.140 |
Why?
|
| False Positive Reactions | 1 | 2018 | 981 | 0.130 |
Why?
|
| Troponin I | 1 | 2020 | 619 | 0.130 |
Why?
|
| Endovascular Procedures | 2 | 2020 | 1979 | 0.130 |
Why?
|
| Oxygen | 4 | 2016 | 4189 | 0.130 |
Why?
|
| Antigens, Neoplasm | 1 | 2003 | 1988 | 0.130 |
Why?
|
| Anxiety Disorders | 1 | 2007 | 2690 | 0.130 |
Why?
|
| Polymerase Chain Reaction | 8 | 2011 | 6171 | 0.130 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2010 | 3923 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 3 | 2012 | 1434 | 0.130 |
Why?
|
| Methylmalonic Acid | 1 | 2015 | 49 | 0.130 |
Why?
|
| Isoantibodies | 1 | 2019 | 679 | 0.130 |
Why?
|
| Biological Transport | 2 | 2013 | 2118 | 0.120 |
Why?
|
| Wilderness Medicine | 1 | 2014 | 7 | 0.120 |
Why?
|
| Anemia, Hemolytic, Congenital | 1 | 2014 | 69 | 0.120 |
Why?
|
| Hemosiderin | 1 | 2014 | 43 | 0.120 |
Why?
|
| Thrombocytopenia | 3 | 2013 | 1179 | 0.120 |
Why?
|
| Aged, 80 and over | 17 | 2018 | 57776 | 0.120 |
Why?
|
| Paresthesia | 1 | 2015 | 161 | 0.120 |
Why?
|
| Laboratories | 1 | 2017 | 463 | 0.120 |
Why?
|
| Calcium | 2 | 2006 | 5756 | 0.120 |
Why?
|
| Structure-Activity Relationship | 1 | 2019 | 3129 | 0.120 |
Why?
|
| Myoglobin | 1 | 2014 | 160 | 0.120 |
Why?
|
| Luminescent Measurements | 1 | 2016 | 405 | 0.120 |
Why?
|
| Albumins | 1 | 2016 | 569 | 0.110 |
Why?
|
| Aircraft | 1 | 2014 | 123 | 0.110 |
Why?
|
| Gene Rearrangement, B-Lymphocyte, Heavy Chain | 2 | 2010 | 92 | 0.110 |
Why?
|
| Antigens, CD20 | 3 | 2008 | 199 | 0.110 |
Why?
|
| Reed-Sternberg Cells | 2 | 2012 | 73 | 0.110 |
Why?
|
| Immunoglobulin G | 2 | 2019 | 4560 | 0.110 |
Why?
|
| Central Nervous System Neoplasms | 3 | 2008 | 895 | 0.110 |
Why?
|
| Tonometry, Ocular | 1 | 2013 | 237 | 0.110 |
Why?
|
| Blood Glucose | 2 | 2021 | 6256 | 0.110 |
Why?
|
| Transferrin | 1 | 2014 | 295 | 0.110 |
Why?
|
| Lymphoma, Primary Cutaneous Anaplastic Large Cell | 1 | 2012 | 9 | 0.110 |
Why?
|
| Gastrointestinal Neoplasms | 2 | 2011 | 990 | 0.110 |
Why?
|
| Receptors, Transferrin | 1 | 2014 | 296 | 0.100 |
Why?
|
| Insulin | 2 | 2006 | 6580 | 0.100 |
Why?
|
| Demyelinating Diseases | 1 | 2015 | 354 | 0.100 |
Why?
|
| Albuminuria | 1 | 2016 | 682 | 0.100 |
Why?
|
| Immunoassay | 1 | 2016 | 752 | 0.100 |
Why?
|
| Hematuria | 1 | 2013 | 235 | 0.100 |
Why?
|
| beta-Thalassemia | 1 | 2014 | 225 | 0.100 |
Why?
|
| Infectious Mononucleosis | 1 | 2012 | 131 | 0.100 |
Why?
|
| Rehydration Solutions | 1 | 2011 | 47 | 0.100 |
Why?
|
| Vitamin B 12 | 1 | 2015 | 527 | 0.100 |
Why?
|
| Hemodilution | 1 | 2011 | 114 | 0.100 |
Why?
|
| Young Adult | 11 | 2015 | 56430 | 0.100 |
Why?
|
| In Situ Hybridization, Fluorescence | 5 | 2012 | 2649 | 0.100 |
Why?
|
| Gastroenteritis | 1 | 2013 | 245 | 0.100 |
Why?
|
| Inflammation | 1 | 2011 | 10638 | 0.100 |
Why?
|
| Knee Joint | 1 | 2020 | 1680 | 0.100 |
Why?
|
| Cation Transport Proteins | 1 | 2014 | 327 | 0.100 |
Why?
|
| Mediastinal Neoplasms | 2 | 2005 | 423 | 0.100 |
Why?
|
| Bone Neoplasms | 1 | 2003 | 2529 | 0.100 |
Why?
|
| Reference Values | 2 | 2010 | 4982 | 0.100 |
Why?
|
| Blood Platelets | 3 | 2020 | 2508 | 0.100 |
Why?
|
| Ki-67 Antigen | 3 | 2012 | 644 | 0.100 |
Why?
|
| Family Characteristics | 1 | 2016 | 1000 | 0.090 |
Why?
|
| Anemia, Sickle Cell | 1 | 2019 | 1018 | 0.090 |
Why?
|
| Aged | 29 | 2020 | 163280 | 0.090 |
Why?
|
| Mycosis Fungoides | 1 | 2012 | 163 | 0.090 |
Why?
|
| Lymphocytosis | 1 | 2011 | 119 | 0.090 |
Why?
|
| Length of Stay | 2 | 2007 | 6309 | 0.090 |
Why?
|
| Nontherapeutic Human Experimentation | 1 | 2010 | 24 | 0.090 |
Why?
|
| Submandibular Gland Diseases | 1 | 2010 | 21 | 0.090 |
Why?
|
| Hematocrit | 1 | 2011 | 636 | 0.090 |
Why?
|
| Protein Subunits | 1 | 2014 | 959 | 0.090 |
Why?
|
| Pseudolymphoma | 1 | 2010 | 30 | 0.090 |
Why?
|
| Genes, Immunoglobulin Heavy Chain | 1 | 2010 | 57 | 0.090 |
Why?
|
| Environment, Controlled | 1 | 2010 | 46 | 0.090 |
Why?
|
| Hemodynamics | 2 | 2011 | 4199 | 0.090 |
Why?
|
| Patient Satisfaction | 1 | 2002 | 3396 | 0.090 |
Why?
|
| Parotid Diseases | 1 | 2010 | 46 | 0.090 |
Why?
|
| Hypertension | 1 | 2010 | 8480 | 0.090 |
Why?
|
| Single-Blind Method | 1 | 2013 | 1590 | 0.090 |
Why?
|
| Sialadenitis | 1 | 2010 | 43 | 0.090 |
Why?
|
| Actigraphy | 1 | 2013 | 488 | 0.090 |
Why?
|
| Uterine Cervical Diseases | 1 | 2010 | 77 | 0.090 |
Why?
|
| Plasma Cells | 2 | 2010 | 591 | 0.090 |
Why?
|
| Sleep Stages | 1 | 2013 | 686 | 0.090 |
Why?
|
| Bone Marrow Cells | 3 | 2007 | 2513 | 0.090 |
Why?
|
| Sodium Chloride | 2 | 2011 | 625 | 0.090 |
Why?
|
| Horner Syndrome | 1 | 2009 | 37 | 0.080 |
Why?
|
| Injury Severity Score | 1 | 2012 | 1014 | 0.080 |
Why?
|
| Animals, Wild | 1 | 2009 | 90 | 0.080 |
Why?
|
| Arthroplasty, Replacement, Knee | 1 | 2020 | 1458 | 0.080 |
Why?
|
| Parents | 1 | 2002 | 3407 | 0.080 |
Why?
|
| Uterine Diseases | 1 | 2010 | 135 | 0.080 |
Why?
|
| Emergency Service, Hospital | 3 | 2009 | 7659 | 0.080 |
Why?
|
| Ristocetin | 1 | 2008 | 26 | 0.080 |
Why?
|
| Elbow Joint | 1 | 2012 | 357 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-rel | 2 | 2005 | 71 | 0.080 |
Why?
|
| Severity of Illness Index | 4 | 2007 | 15540 | 0.080 |
Why?
|
| Cardiomyopathies | 1 | 2020 | 1912 | 0.080 |
Why?
|
| Time Factors | 10 | 2019 | 40075 | 0.080 |
Why?
|
| Pulmonary Gas Exchange | 1 | 2010 | 382 | 0.080 |
Why?
|
| Blepharoptosis | 1 | 2009 | 143 | 0.080 |
Why?
|
| Craniocerebral Trauma | 1 | 2012 | 482 | 0.080 |
Why?
|
| Burkitt Lymphoma | 1 | 2010 | 327 | 0.080 |
Why?
|
| Multiple Myeloma | 1 | 2005 | 5181 | 0.080 |
Why?
|
| Logistic Models | 3 | 2013 | 13408 | 0.080 |
Why?
|
| Autoimmune Diseases | 2 | 2010 | 2133 | 0.080 |
Why?
|
| Thrombelastography | 2 | 2020 | 164 | 0.080 |
Why?
|
| Fluid Therapy | 1 | 2011 | 593 | 0.080 |
Why?
|
| Knee Injuries | 1 | 2012 | 490 | 0.070 |
Why?
|
| Pulmonary Diffusing Capacity | 1 | 2007 | 88 | 0.070 |
Why?
|
| Gangrene | 1 | 2007 | 82 | 0.070 |
Why?
|
| Double-Blind Method | 3 | 2013 | 12026 | 0.070 |
Why?
|
| Pulmonary Alveoli | 1 | 2010 | 675 | 0.070 |
Why?
|
| Analgesics, Opioid | 1 | 2003 | 3674 | 0.070 |
Why?
|
| Hematinics | 1 | 2009 | 281 | 0.070 |
Why?
|
| Bed Rest | 1 | 2007 | 84 | 0.070 |
Why?
|
| Hyponatremia | 1 | 2009 | 298 | 0.070 |
Why?
|
| Immunoenzyme Techniques | 2 | 2007 | 1799 | 0.070 |
Why?
|
| Point-of-Care Systems | 2 | 2013 | 1177 | 0.070 |
Why?
|
| Nifedipine | 1 | 2007 | 226 | 0.070 |
Why?
|
| Survival Rate | 7 | 2012 | 12788 | 0.070 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2010 | 8428 | 0.070 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 1 | 2008 | 169 | 0.070 |
Why?
|
| Iatrogenic Disease | 1 | 2009 | 547 | 0.070 |
Why?
|
| Atmospheric Pressure | 2 | 2016 | 47 | 0.070 |
Why?
|
| Prognosis | 10 | 2012 | 29063 | 0.070 |
Why?
|
| Albuterol | 1 | 2007 | 208 | 0.070 |
Why?
|
| Gene Rearrangement, B-Lymphocyte | 1 | 2006 | 111 | 0.070 |
Why?
|
| Arabidopsis Proteins | 1 | 2007 | 262 | 0.070 |
Why?
|
| Osmotic Fragility | 1 | 2005 | 37 | 0.070 |
Why?
|
| Reticulocyte Count | 1 | 2005 | 37 | 0.060 |
Why?
|
| Mutation, Missense | 1 | 2014 | 2564 | 0.060 |
Why?
|
| Monitoring, Physiologic | 1 | 2013 | 1738 | 0.060 |
Why?
|
| Erythropoietin | 1 | 2009 | 726 | 0.060 |
Why?
|
| Iliac Artery | 1 | 2007 | 364 | 0.060 |
Why?
|
| Cell Proliferation | 3 | 2012 | 10481 | 0.060 |
Why?
|
| Lymphocytes | 2 | 2012 | 2617 | 0.060 |
Why?
|
| Hospitals, Urban | 2 | 2007 | 499 | 0.060 |
Why?
|
| Zinc Radioisotopes | 1 | 2004 | 3 | 0.060 |
Why?
|
| Cadmium Radioisotopes | 1 | 2004 | 2 | 0.060 |
Why?
|
| Hospitalization | 4 | 2009 | 10262 | 0.060 |
Why?
|
| Erythrocyte Count | 1 | 2005 | 163 | 0.060 |
Why?
|
| RNA, Viral | 3 | 2011 | 2902 | 0.060 |
Why?
|
| Brain Neoplasms | 2 | 2008 | 8863 | 0.060 |
Why?
|
| Awareness | 1 | 2009 | 640 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2010 | 987 | 0.060 |
Why?
|
| Megakaryocytes | 1 | 2008 | 545 | 0.060 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2005 | 640 | 0.060 |
Why?
|
| Duodenal Neoplasms | 1 | 2004 | 106 | 0.060 |
Why?
|
| Sulfones | 1 | 2007 | 437 | 0.060 |
Why?
|
| Sodium | 1 | 2009 | 1623 | 0.060 |
Why?
|
| Arabidopsis | 1 | 2007 | 459 | 0.060 |
Why?
|
| Biopsy | 4 | 2012 | 6756 | 0.060 |
Why?
|
| Prevalence | 1 | 2021 | 15226 | 0.060 |
Why?
|
| Methotrexate | 3 | 2005 | 1727 | 0.060 |
Why?
|
| Survival Analysis | 5 | 2011 | 10252 | 0.060 |
Why?
|
| Purines | 1 | 2007 | 594 | 0.060 |
Why?
|
| Genes, bcl-2 | 1 | 2003 | 122 | 0.060 |
Why?
|
| Cardiotonic Agents | 1 | 2006 | 535 | 0.060 |
Why?
|
| Linear Models | 2 | 2015 | 5952 | 0.060 |
Why?
|
| Retrospective Studies | 8 | 2019 | 77449 | 0.050 |
Why?
|
| Tennessee | 1 | 2002 | 117 | 0.050 |
Why?
|
| Skin Neoplasms | 3 | 2012 | 5686 | 0.050 |
Why?
|
| Child | 14 | 2014 | 77709 | 0.050 |
Why?
|
| Travel | 1 | 2008 | 788 | 0.050 |
Why?
|
| Homeostasis | 1 | 2014 | 3340 | 0.050 |
Why?
|
| Stereotaxic Techniques | 1 | 2005 | 536 | 0.050 |
Why?
|
| Lymphocyte Count | 1 | 2005 | 793 | 0.050 |
Why?
|
| Heart Rate | 2 | 2016 | 4091 | 0.050 |
Why?
|
| Femoral Artery | 1 | 2007 | 845 | 0.050 |
Why?
|
| Automation | 1 | 2005 | 584 | 0.050 |
Why?
|
| Exercise | 2 | 2016 | 5615 | 0.050 |
Why?
|
| Combined Modality Therapy | 4 | 2008 | 8642 | 0.050 |
Why?
|
| Platelet Count | 1 | 2005 | 781 | 0.050 |
Why?
|
| Chest Pain | 1 | 2009 | 1114 | 0.050 |
Why?
|
| Socioeconomic Factors | 1 | 2016 | 7785 | 0.050 |
Why?
|
| Adolescent | 14 | 2012 | 85781 | 0.050 |
Why?
|
| Nausea | 1 | 2005 | 673 | 0.050 |
Why?
|
| Coronary Artery Disease | 1 | 2021 | 6487 | 0.050 |
Why?
|
| Leg | 1 | 2007 | 1116 | 0.050 |
Why?
|
| Movement Disorders | 1 | 2005 | 445 | 0.050 |
Why?
|
| Hospital Costs | 1 | 2007 | 985 | 0.050 |
Why?
|
| Helicobacter Infections | 1 | 2004 | 386 | 0.050 |
Why?
|
| Models, Biological | 1 | 2017 | 9583 | 0.050 |
Why?
|
| Interferon Regulatory Factors | 3 | 2009 | 270 | 0.050 |
Why?
|
| Leukocyte Count | 1 | 2005 | 1588 | 0.050 |
Why?
|
| United States | 6 | 2021 | 69872 | 0.050 |
Why?
|
| Follow-Up Studies | 6 | 2011 | 39050 | 0.050 |
Why?
|
| Paranasal Sinus Neoplasms | 1 | 2003 | 234 | 0.050 |
Why?
|
| Germinal Center | 1 | 2003 | 377 | 0.050 |
Why?
|
| Nasal Cavity | 1 | 2003 | 313 | 0.050 |
Why?
|
| Nose Neoplasms | 1 | 2003 | 246 | 0.050 |
Why?
|
| Treatment Outcome | 11 | 2011 | 63114 | 0.050 |
Why?
|
| Myocardial Infarction | 2 | 2020 | 11727 | 0.050 |
Why?
|
| Hospitals | 1 | 2014 | 3952 | 0.050 |
Why?
|
| Sarcoma, Kaposi | 1 | 2003 | 370 | 0.050 |
Why?
|
| Fractures, Bone | 1 | 2012 | 1947 | 0.050 |
Why?
|
| Immunologic Factors | 1 | 2009 | 1580 | 0.050 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2011 | 1596 | 0.040 |
Why?
|
| Antigens, CD | 2 | 2012 | 4026 | 0.040 |
Why?
|
| Zinc | 1 | 2004 | 684 | 0.040 |
Why?
|
| Parietal Lobe | 1 | 2005 | 838 | 0.040 |
Why?
|
| Blotting, Southern | 2 | 2011 | 803 | 0.040 |
Why?
|
| Chromosomes, Plant | 1 | 2019 | 19 | 0.040 |
Why?
|
| Tetraploidy | 1 | 2019 | 29 | 0.040 |
Why?
|
| Intensive Care Units | 1 | 2013 | 3679 | 0.040 |
Why?
|
| Synteny | 1 | 2019 | 79 | 0.040 |
Why?
|
| Cohort Studies | 5 | 2015 | 40561 | 0.040 |
Why?
|
| Genome, Plant | 1 | 2019 | 78 | 0.040 |
Why?
|
| DNA, Viral | 1 | 2005 | 2225 | 0.040 |
Why?
|
| Antithrombins | 1 | 2022 | 304 | 0.040 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2005 | 783 | 0.040 |
Why?
|
| Genotype | 1 | 2013 | 12951 | 0.040 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2008 | 2455 | 0.040 |
Why?
|
| Suicide, Attempted | 1 | 2006 | 1221 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 2 | 2012 | 193 | 0.040 |
Why?
|
| Postoperative Complications | 1 | 2020 | 15295 | 0.040 |
Why?
|
| Sclerosis | 2 | 2010 | 213 | 0.040 |
Why?
|
| Reproducibility of Results | 3 | 2020 | 19905 | 0.040 |
Why?
|
| Sensitivity and Specificity | 2 | 2020 | 14722 | 0.040 |
Why?
|
| Anemia, Hemolytic, Autoimmune | 1 | 2019 | 142 | 0.040 |
Why?
|
| Coronary Angiography | 1 | 2009 | 4577 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2020 | 10943 | 0.040 |
Why?
|
| Stents | 2 | 2020 | 3280 | 0.040 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2012 | 3658 | 0.040 |
Why?
|
| Pyridones | 1 | 2022 | 712 | 0.040 |
Why?
|
| Child, Preschool | 6 | 2014 | 41006 | 0.040 |
Why?
|
| Plant Proteins | 1 | 2019 | 364 | 0.040 |
Why?
|
| Cross-Sectional Studies | 2 | 2016 | 25043 | 0.040 |
Why?
|
| NF-kappa B | 1 | 2005 | 2499 | 0.030 |
Why?
|
| Recurrence | 4 | 2011 | 8340 | 0.030 |
Why?
|
| Piperazines | 1 | 2007 | 2488 | 0.030 |
Why?
|
| Kinetics | 1 | 2004 | 6473 | 0.030 |
Why?
|
| Gene Expression Profiling | 3 | 2007 | 9438 | 0.030 |
Why?
|
| Burns | 1 | 2007 | 1815 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2009 | 20129 | 0.030 |
Why?
|
| Viral Proteins | 1 | 2003 | 1900 | 0.030 |
Why?
|
| Acute Coronary Syndrome | 1 | 2009 | 2337 | 0.030 |
Why?
|
| Indicators and Reagents | 1 | 2016 | 462 | 0.030 |
Why?
|
| Gene Expression Regulation | 1 | 2014 | 12072 | 0.030 |
Why?
|
| Carotid Arteries | 1 | 2020 | 952 | 0.030 |
Why?
|
| Decision Making | 1 | 2009 | 3887 | 0.030 |
Why?
|
| Prospective Studies | 4 | 2020 | 53288 | 0.030 |
Why?
|
| Stomach Neoplasms | 1 | 2004 | 1333 | 0.030 |
Why?
|
| False Negative Reactions | 1 | 2016 | 588 | 0.030 |
Why?
|
| Adenosine Triphosphatases | 1 | 2019 | 839 | 0.030 |
Why?
|
| Syndecan-1 | 2 | 2007 | 165 | 0.030 |
Why?
|
| Blood Pressure | 1 | 2010 | 8554 | 0.030 |
Why?
|
| Proteomics | 1 | 2007 | 3638 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2010 | 7913 | 0.030 |
Why?
|
| Selection, Genetic | 1 | 2019 | 914 | 0.030 |
Why?
|
| Intracranial Hemorrhages | 1 | 2020 | 855 | 0.030 |
Why?
|
| Urinalysis | 1 | 2016 | 369 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2022 | 3913 | 0.030 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2006 | 4386 | 0.030 |
Why?
|
| beta-Globins | 1 | 2014 | 113 | 0.030 |
Why?
|
| Neoplasm Staging | 4 | 2011 | 11031 | 0.030 |
Why?
|
| Pain Measurement | 1 | 2003 | 3420 | 0.030 |
Why?
|
| Pregnancy | 1 | 2015 | 29144 | 0.030 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2006 | 4479 | 0.030 |
Why?
|
| Electrocardiography | 1 | 2006 | 6442 | 0.030 |
Why?
|
| Protein Stability | 1 | 2014 | 557 | 0.030 |
Why?
|
| B-Lymphocytes | 1 | 2006 | 4665 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2013 | 9959 | 0.030 |
Why?
|
| Thyroid Neoplasms | 1 | 2005 | 2282 | 0.030 |
Why?
|
| Genes, T-Cell Receptor | 1 | 2011 | 29 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2011 | 18029 | 0.030 |
Why?
|
| Coronary Artery Bypass | 1 | 2021 | 2289 | 0.030 |
Why?
|
| Isotonic Solutions | 1 | 2011 | 119 | 0.030 |
Why?
|
| Phylogeny | 1 | 2019 | 2803 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2012 | 9239 | 0.020 |
Why?
|
| Pyrazoles | 1 | 2022 | 1972 | 0.020 |
Why?
|
| Immunoglobulin Light Chains | 1 | 2012 | 277 | 0.020 |
Why?
|
| Maryland | 1 | 2011 | 276 | 0.020 |
Why?
|
| Brain Edema | 1 | 2016 | 617 | 0.020 |
Why?
|
| Antithrombin III | 1 | 2011 | 128 | 0.020 |
Why?
|
| Electric Conductivity | 1 | 2011 | 411 | 0.020 |
Why?
|
| Biopsy, Fine-Needle | 2 | 2006 | 1094 | 0.020 |
Why?
|
| Quantitative Trait Loci | 1 | 2019 | 2019 | 0.020 |
Why?
|
| Predictive Value of Tests | 3 | 2011 | 15076 | 0.020 |
Why?
|
| Animals | 5 | 2011 | 168757 | 0.020 |
Why?
|
| Spectroscopy, Near-Infrared | 1 | 2016 | 721 | 0.020 |
Why?
|
| Software | 1 | 2005 | 4443 | 0.020 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2003 | 4554 | 0.020 |
Why?
|
| Cytogenetic Analysis | 1 | 2011 | 295 | 0.020 |
Why?
|
| Equipment and Supplies | 1 | 2013 | 281 | 0.020 |
Why?
|
| Observer Variation | 1 | 2016 | 2593 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2011 | 6538 | 0.020 |
Why?
|
| Epoetin Alfa | 1 | 2009 | 83 | 0.020 |
Why?
|
| Belgium | 1 | 2009 | 103 | 0.020 |
Why?
|
| Amino Acid Substitution | 1 | 2014 | 1791 | 0.020 |
Why?
|
| Inappropriate ADH Syndrome | 1 | 2009 | 61 | 0.020 |
Why?
|
| Radiotherapy | 2 | 2008 | 1533 | 0.020 |
Why?
|
| Genes, T-Cell Receptor gamma | 1 | 2008 | 16 | 0.020 |
Why?
|
| Cell Differentiation | 2 | 2003 | 11483 | 0.020 |
Why?
|
| Agglutination | 1 | 2008 | 43 | 0.020 |
Why?
|
| Carotid Artery, Internal, Dissection | 1 | 2009 | 45 | 0.020 |
Why?
|
| Genes, T-Cell Receptor beta | 1 | 2008 | 71 | 0.020 |
Why?
|
| DNA-Binding Proteins | 2 | 2003 | 9648 | 0.020 |
Why?
|
| Boston | 2 | 2011 | 9313 | 0.020 |
Why?
|
| Bernard-Soulier Syndrome | 1 | 2008 | 7 | 0.020 |
Why?
|
| Bone Marrow Examination | 1 | 2008 | 157 | 0.020 |
Why?
|
| Plasma | 1 | 2011 | 575 | 0.020 |
Why?
|
| Infant, Newborn | 2 | 2012 | 25625 | 0.020 |
Why?
|
| Tissue Array Analysis | 1 | 2010 | 553 | 0.020 |
Why?
|
| Exons | 1 | 2014 | 2437 | 0.020 |
Why?
|
| Sjogren's Syndrome | 1 | 2010 | 233 | 0.020 |
Why?
|
| Karyotyping | 1 | 2010 | 1243 | 0.020 |
Why?
|
| Necrosis | 1 | 2012 | 1643 | 0.020 |
Why?
|
| Disease Progression | 3 | 2012 | 13284 | 0.020 |
Why?
|
| Ticlopidine | 1 | 2013 | 899 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2011 | 11524 | 0.020 |
Why?
|
| Intestinal Obstruction | 1 | 2011 | 424 | 0.020 |
Why?
|
| Pediatrics | 1 | 2002 | 3475 | 0.020 |
Why?
|
| Receptors, Complement 3d | 1 | 2007 | 118 | 0.020 |
Why?
|
| Hospitals, General | 1 | 2011 | 749 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2002 | 3336 | 0.020 |
Why?
|
| Costs and Cost Analysis | 1 | 2013 | 1681 | 0.020 |
Why?
|
| Splenomegaly | 1 | 2007 | 190 | 0.020 |
Why?
|
| Burn Units | 1 | 2007 | 136 | 0.020 |
Why?
|
| Gene Expression Regulation, Plant | 1 | 2007 | 201 | 0.020 |
Why?
|
| Kidney Transplantation | 1 | 2002 | 4251 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2016 | 2540 | 0.020 |
Why?
|
| Radiotherapy Dosage | 2 | 2003 | 2879 | 0.020 |
Why?
|
| Asia | 1 | 2008 | 610 | 0.020 |
Why?
|
| Infant | 2 | 2012 | 35136 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2011 | 2274 | 0.020 |
Why?
|
| Clone Cells | 1 | 2010 | 1692 | 0.020 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2011 | 576 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2011 | 1770 | 0.020 |
Why?
|
| Mice | 2 | 2011 | 81183 | 0.020 |
Why?
|
| Thrombosis | 1 | 2020 | 2968 | 0.020 |
Why?
|
| Medical Records | 1 | 2011 | 1413 | 0.020 |
Why?
|
| Cerebrovascular Circulation | 1 | 2016 | 2731 | 0.020 |
Why?
|
| Hypoglycemia | 1 | 2013 | 861 | 0.020 |
Why?
|
| Genetic Markers | 1 | 2012 | 2634 | 0.020 |
Why?
|
| Phototherapy | 1 | 2008 | 377 | 0.020 |
Why?
|
| Propofol | 1 | 2011 | 629 | 0.020 |
Why?
|
| Thyroiditis | 1 | 2005 | 85 | 0.020 |
Why?
|
| North America | 1 | 2008 | 1249 | 0.020 |
Why?
|
| DNA, Neoplasm | 1 | 2010 | 1758 | 0.020 |
Why?
|
| Microscopy, Electron | 1 | 2008 | 2645 | 0.010 |
Why?
|
| Lymphatic Metastasis | 1 | 2012 | 2924 | 0.010 |
Why?
|
| World Health Organization | 1 | 2010 | 1318 | 0.010 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 1 | 2007 | 260 | 0.010 |
Why?
|
| TNF Receptor-Associated Factor 1 | 1 | 2003 | 50 | 0.010 |
Why?
|
| Microfilament Proteins | 1 | 2009 | 1152 | 0.010 |
Why?
|
| Genetic Variation | 1 | 2019 | 6544 | 0.010 |
Why?
|
| Equipment Design | 1 | 2011 | 3582 | 0.010 |
Why?
|
| Syndecans | 1 | 2003 | 79 | 0.010 |
Why?
|
| Cerebral Angiography | 1 | 2009 | 1285 | 0.010 |
Why?
|
| Risk Assessment | 3 | 2010 | 23338 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2003 | 12208 | 0.010 |
Why?
|
| Postoperative Care | 1 | 2009 | 1486 | 0.010 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2011 | 3479 | 0.010 |
Why?
|
| Coronary Stenosis | 1 | 2009 | 834 | 0.010 |
Why?
|
| Chronic Disease | 2 | 2010 | 9146 | 0.010 |
Why?
|
| Gastritis | 1 | 2004 | 196 | 0.010 |
Why?
|
| Hospitals, Teaching | 1 | 2007 | 1179 | 0.010 |
Why?
|
| Terminology as Topic | 1 | 2010 | 1547 | 0.010 |
Why?
|
| Fatal Outcome | 1 | 2007 | 1850 | 0.010 |
Why?
|
| HIV Infections | 1 | 2009 | 16718 | 0.010 |
Why?
|
| RNA, Nuclear | 1 | 2002 | 30 | 0.010 |
Why?
|
| Epitope Mapping | 1 | 2003 | 311 | 0.010 |
Why?
|
| STAT1 Transcription Factor | 1 | 2003 | 320 | 0.010 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2003 | 876 | 0.010 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2003 | 443 | 0.010 |
Why?
|
| Hemorrhage | 1 | 2013 | 3461 | 0.010 |
Why?
|
| Aspirin | 1 | 2013 | 3282 | 0.010 |
Why?
|
| Syndrome | 1 | 2008 | 3251 | 0.010 |
Why?
|
| International Cooperation | 1 | 2008 | 1420 | 0.010 |
Why?
|
| Interleukin-13 | 1 | 2003 | 389 | 0.010 |
Why?
|
| Europe | 1 | 2008 | 3339 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 2007 | 2971 | 0.010 |
Why?
|
| Helicobacter pylori | 1 | 2004 | 382 | 0.010 |
Why?
|
| Lymphocyte Activation | 1 | 2012 | 5524 | 0.010 |
Why?
|
| Risk | 1 | 2013 | 9687 | 0.010 |
Why?
|
| Glutamate Decarboxylase | 1 | 2002 | 245 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2011 | 6895 | 0.010 |
Why?
|
| Hypothyroidism | 1 | 2005 | 658 | 0.010 |
Why?
|
| Academic Medical Centers | 1 | 2011 | 2759 | 0.010 |
Why?
|
| Mutation | 3 | 2014 | 29786 | 0.010 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 2003 | 548 | 0.010 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2008 | 1660 | 0.010 |
Why?
|
| Immunotherapy | 1 | 2016 | 4445 | 0.010 |
Why?
|
| Neprilysin | 1 | 2003 | 439 | 0.010 |
Why?
|
| Health Care Surveys | 1 | 2007 | 2453 | 0.010 |
Why?
|
| Thyroidectomy | 1 | 2005 | 879 | 0.010 |
Why?
|
| Macaca fascicularis | 1 | 2002 | 915 | 0.010 |
Why?
|
| Critical Illness | 1 | 2013 | 2670 | 0.010 |
Why?
|
| Immunoblotting | 1 | 2003 | 1682 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2009 | 6622 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2003 | 705 | 0.010 |
Why?
|
| Proteoglycans | 1 | 2003 | 835 | 0.010 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2010 | 2942 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2019 | 15519 | 0.010 |
Why?
|
| Meningeal Neoplasms | 1 | 2008 | 1241 | 0.010 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2003 | 2505 | 0.010 |
Why?
|
| Eye Diseases | 1 | 2003 | 669 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2005 | 35421 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 2005 | 3616 | 0.010 |
Why?
|
| Health Surveys | 1 | 2007 | 4037 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2009 | 8324 | 0.010 |
Why?
|
| Immunosuppressive Agents | 1 | 2009 | 4149 | 0.010 |
Why?
|
| Energy Metabolism | 1 | 2007 | 2899 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2003 | 3870 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 2009 | 5021 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2010 | 12354 | 0.010 |
Why?
|
| Islets of Langerhans | 1 | 2002 | 1352 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2003 | 6314 | 0.010 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2010 | 5172 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 2003 | 6386 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2011 | 21746 | 0.010 |
Why?
|
| Trans-Activators | 1 | 2003 | 2924 | 0.010 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2003 | 2948 | 0.010 |
Why?
|
| Antibodies, Viral | 1 | 2003 | 3176 | 0.010 |
Why?
|
| Membrane Glycoproteins | 1 | 2003 | 3768 | 0.010 |
Why?
|
| Health Status | 1 | 2005 | 4034 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2005 | 12245 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2003 | 13815 | 0.010 |
Why?
|
| Age Factors | 1 | 2007 | 18370 | 0.010 |
Why?
|
| Signal Transduction | 2 | 2003 | 23403 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2003 | 18111 | 0.010 |
Why?
|
| Apoptosis | 1 | 2005 | 9727 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2005 | 16689 | 0.010 |
Why?
|
| Proteins | 1 | 2003 | 6103 | 0.000 |
Why?
|
| Antineoplastic Agents | 1 | 2009 | 13695 | 0.000 |
Why?
|
| Anti-Bacterial Agents | 1 | 2004 | 7181 | 0.000 |
Why?
|
| Algorithms | 1 | 2003 | 13881 | 0.000 |
Why?
|
| Risk Factors | 1 | 2007 | 72290 | 0.000 |
Why?
|